Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma, Mantle-Cell 7Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell, Marginal Zone 3Leukemia, B-Cell 3Leukemia 3Lymphoma, Follicular 2Lymphoma 2Waldenstrom Macroglobulinemia 1Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Hematologic Diseases 1Dendritic Cell Sarcoma, Interdigitating 1Chromosome 17 deletion 1Burkitt Lymphoma 1

Interventions

glofitamab 2Rituximab 2Cyclophosphamide 2zanubrutinib 1pirtobrutinib 1pegfilgrastim 1obinutuzumab 1mirabegron 1Vincristine 1Specimen Handling 1Prednisolone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Lenalidomide 1Doxorubicin 1Dexrazoxane 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Dendritic Cell Sarcoma, Interdigitating × pirtobrutinib × Clear all
NCT07255963 2025-12-01

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
29 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡